Trials / Recruiting
RecruitingNCT05444088
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
An Open-label, Multicenter Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 129 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab | intravenous infusion |
| DRUG | Bevacizumab | intravenous infusion |
| DRUG | SHR-8068 | intravenous infusion |
Timeline
- Start date
- 2022-08-02
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2022-07-05
- Last updated
- 2024-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05444088. Inclusion in this directory is not an endorsement.